2296 related articles for article (PubMed ID: 21500185)
1. SD-OCT pattern of retinal venous occlusion with cystoid macular edema treated with Ozurdex®.
Coscas G; Coscas F; Zucchiatti I; Glacet-Bernard A; Soubrane G; Souïed E
Eur J Ophthalmol; 2011; 21(5):631-6. PubMed ID: 21500185
[TBL] [Abstract][Full Text] [Related]
2. Impact of intravitreal dexamethasone implant (Ozurdex) on macular morphology and function.
Querques G; Lattanzio R; Querques L; Triolo G; Cascavilla ML; Cavallero E; Del Turco C; Casalino G; Bandello F
Retina; 2014 Feb; 34(2):330-41. PubMed ID: 23945638
[TBL] [Abstract][Full Text] [Related]
3. SAFETY AND FEASIBILITY OF A NOVEL 25-GAUGE BIODEGRADABLE IMPLANT OF DEXAMETHASONE FOR TREATMENT OF MACULAR EDEMA ASSOCIATED WITH RETINAL VEIN OCCLUSION: A PHASE I CLINICAL TRIAL.
Cunha RB; Siqueira RC; Messias A; Scott IU; Fialho SL; Cunha-Junior ADS; Jorge R
Retin Cases Brief Rep; 2018 Winter; 12(1):50-58. PubMed ID: 27632583
[TBL] [Abstract][Full Text] [Related]
4. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of foveal photoreceptor layer in eyes with macular edema associated with branch retinal vein occlusion after ozurdex treatment.
Altunel O; Duru N; Goktas A; Ozkose A; Goktas E; Atas M
Int Ophthalmol; 2017 Apr; 37(2):333-339. PubMed ID: 27221365
[TBL] [Abstract][Full Text] [Related]
6. OUTER RETINAL LAYER CHANGES AFTER DEXAMETHASONE IMPLANT FOR CENTRAL RETINAL VEIN OCCLUSION.
Battaglia Parodi M; Iacono P; Scaramuzzi M; Bandello F
Retina; 2017 Oct; 37(10):1888-1895. PubMed ID: 28030428
[TBL] [Abstract][Full Text] [Related]
7. Two or more dexamethasone intravitreal implants in treatment-naïve patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study.
Dugel PU; Capone A; Singer MA; Dreyer RF; Dodwell DG; Roth DB; Shi R; Walt JG; Scott LC; Hollander DA;
BMC Ophthalmol; 2015 Sep; 15():118. PubMed ID: 26337664
[TBL] [Abstract][Full Text] [Related]
8. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion.
Singer MA; Bell DJ; Woods P; Pollard J; Boord T; Herro A; Porbandarwalla S
Retina; 2012 Jul; 32(7):1289-94. PubMed ID: 22466480
[TBL] [Abstract][Full Text] [Related]
9. Spectral domain optical coherence tomography changes following intravitreal dexamethasone implant, Ozurdex® in patients with uveitic cystoid macular edema.
Bansal P; Agarwal A; Gupta V; Singh R; Gupta A
Indian J Ophthalmol; 2015 May; 63(5):416-22. PubMed ID: 26139803
[TBL] [Abstract][Full Text] [Related]
10. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.
Ozkaya A; Tarakcioglu HN; Tanir I
Optom Vis Sci; 2018 Dec; 95(12):1149-1154. PubMed ID: 30451802
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
12. [Dexamethason implant in the treatment of macular edema in retinal vein occlusion and intraocular inflammatory disease].
Brunner M; Haueter I; Valmaggia C
Klin Monbl Augenheilkd; 2013 Apr; 230(4):396-400. PubMed ID: 23629790
[TBL] [Abstract][Full Text] [Related]
13. INTRAVITREAL DEXAMETHASONE IMPLANT FOR THE TREATMENT OF REFRACTORY MACULAR EDEMA IN RETINAL VASCULAR DISEASES: Results of the KKESH International Collaborative Retina Study Group.
Alshahrani ST; Dolz-Marco R; Gallego-Pinazo R; Diaz-Llopis M; Arevalo JF;
Retina; 2016 Jan; 36(1):131-6. PubMed ID: 26079477
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario.
Simsek M; Citirik M; Ozates S; Ozkoyuncu D
Indian J Ophthalmol; 2018 Jun; 66(6):831-836. PubMed ID: 29785994
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Age on Dexamethasone Intravitreal Implant (Ozurdex®) Response in Macular Edema Secondary to Branch Retinal Vein Occlusion.
Altunel O; Göktaş A; Duru N; Özköse A; Arifoğlu HB; Ataş M
Semin Ophthalmol; 2018; 33(2):179-184. PubMed ID: 27599562
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal dexamethasone implant for the treatment of macular edema after retinal vein occlusion in a clinical setting.
Ferrini W; Ambresin A
Klin Monbl Augenheilkd; 2013 Apr; 230(4):423-6. PubMed ID: 23629796
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
[TBL] [Abstract][Full Text] [Related]
18. Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France.
Korobelnik JF; Kodjikian L; Delcourt C; Gualino V; Leaback R; Pinchinat S; Velard ME
Graefes Arch Clin Exp Ophthalmol; 2016 Dec; 254(12):2307-2318. PubMed ID: 27286894
[TBL] [Abstract][Full Text] [Related]
19. Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience.
Blanc J; Deschasse C; Kodjikian L; Dot C; Bron AM; Creuzot-Garcher C
Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1441-1448. PubMed ID: 29855706
[TBL] [Abstract][Full Text] [Related]
20. Early effects of dexamethasone implant on macular morphology and visual function in patients with macular edema secondary to retinal vein occlusion.
Veritti D; Macor S; Lanzetta P
Ophthalmologica; 2014; 232(3):144-8. PubMed ID: 25300393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
